FUSN — Fusion Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.83bn
- $1.67bn
- $2.07m
Annual income statement for Fusion Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 1.44 | 1.46 | 2.07 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 18.2 | 37.9 | 83.5 | 89.5 | 101 |
| Operating Profit | -18.2 | -37.9 | -82 | -88 | -99.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15.9 | -75.7 | -81.2 | -89.4 | -94.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.2 | -78.3 | -81 | -87.6 | -94.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.2 | -78.3 | -81 | -87.6 | -94.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.2 | -79.7 | -81 | -87.6 | -94.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.389 | -1.91 | -1.9 | -2 | -1.45 |
| Dividends per Share |